Healthpeak Properties
DOC
$16.74
+0.30%
Healthpeak Properties, Inc. is a real estate investment trust (REIT) specializing in healthcare facilities, owning a diversified portfolio of approximately 700 properties primarily focused on medical office and life science assets, with additional holdings in senior housing, hospitals, and skilled nursing facilities. The company is a prominent player in the healthcare REIT sector, distinguished by its strategic focus on high-barrier-to-entry, mission-critical properties in the outpatient medical and life science segments. The current investor narrative centers on the company's ability to navigate a challenging macroeconomic environment marked by higher interest rates, which pressure REIT valuations, while also focusing on the stability and growth potential of its core medical office and life science assets, which are seen as defensive yet growth-oriented within the real estate landscape.…
DOC
Healthpeak Properties
$16.74
Investment Opinion: Should I buy DOC Today?
Rating & Thesis: Hold. Healthpeak presents a conflicted profile of strong underlying cash flow and defensive assets offset by extreme valuation, technical weakness, and macro headwinds, resulting in a neutral stance aligned with the mixed analyst sentiment (e.g., Argus downgrade to Hold).
Supporting Evidence: The Hold rating is supported by four key data points: 1) The stock trades at a forward P/E of 82.6x, an extreme premium demanding flawless execution, 2) Revenue growth is stable but modest at 3.07% YoY, 3) Profitability is volatile with a TTM net margin of only 2.53%, and 4) The 7.6% dividend yield is well-covered by substantial TTM FCF of $1.17B, providing a floor for income-oriented investors. However, the Price/Book of 1.49 is reasonable, suggesting the asset base is not grossly overvalued.
Risks & Conditions: The two biggest risks are a failure to achieve the projected EPS recovery, triggering multiple compression, and a further rise in interest rates pressuring all REIT valuations. This Hold would upgrade to a Buy if the forward P/E compresses below 50x on sustained earnings growth or if the stock establishes a firm technical bottom above $18.50. It would downgrade to a Sell if quarterly revenue growth decelerates below 2% or if the stock breaks decisively below the $15.71 support. Currently, the stock is overvalued on an earnings basis but fairly valued on an asset (P/B) and cash flow (P/CF of 8.74) basis.
Sign up to view all
DOC 12-Month Price Forecast
Healthpeak is a classic 'show me' story trapped between macro headwinds and company-specific promise. The high yield and valuable asset base prevent a full bearish stance, but the extreme P/E and poor technicals argue against bullishness. The neutral view hinges on the base case probability (55%) of a grinding, range-bound recovery. The stance would upgrade to bullish on clear evidence of earnings acceleration (EPS >$0.32) combined with a sustained technical breakout above $18.50. It would turn bearish on a breakdown below $15.71 coupled with an EPS miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthpeak Properties's 12-month outlook, with a consensus price target around $21.76 and implied upside of +30.0% versus the current price.
Average Target
$21.76
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$13 - $22
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, indicating this is a mid-cap stock with moderate institutional interest. The consensus sentiment appears mixed, as evidenced by recent rating actions: in February 2026, Argus Research downgraded the stock from Buy to Hold, while Evercore ISI maintained an Outperform rating, suggesting a lack of clear directional conviction among covering firms. The target price range implied by revenue and EPS estimates is wide, with estimated revenue for the forward period ranging from $2.93 billion to $3.25 billion and EPS from $0.2802 to $0.32045; this broad spread signals high uncertainty regarding the company's near-term financial performance, which is typical for REITs in a volatile interest rate environment, and makes deriving a precise price target challenging without explicit analyst price targets provided in the data.
Bulls vs Bears: DOC Investment Factors
The evidence currently leans bearish, primarily due to the stock's severe technical breakdown, extreme valuation multiples, and volatile profitability in the face of a hostile interest rate environment for REITs. The bull case rests on the defensive asset quality, strong cash flow, and an anticipated earnings recovery that would normalize the P/E. The single most important tension in the investment debate is whether the company's projected EPS recovery to $0.305 materializes as expected. If it does, the forward P/E compresses to a more reasonable level, supporting the bull case. If earnings disappoint or stagnate, the current sky-high multiples are unjustified, and the stock faces significant further downside.
Bullish
- Strong Cash Flow & Dividend Coverage: The company generates robust free cash flow, with TTM FCF of $1.17 billion, providing ample coverage for its 7.6% dividend yield. The dividend payout ratio based on earnings is high at 11.9x, but this is a misleading GAAP metric; coverage from substantial operating cash flow is secure.
- Defensive, Mission-Critical Asset Base: Healthpeak's portfolio of approximately 700 medical office and life science properties provides a defensive revenue stream. These outpatient and research assets are less economically sensitive, supporting stable occupancy and rent collection, as evidenced by consistent quarterly revenue in the $700 million range.
- Analyst Expects Significant Earnings Recovery: The forward P/E of 82.6x, while high, is half the trailing P/E of 156.9x, indicating analysts project a near-doubling of EPS from $0.16 in Q4 2025 to an estimated $0.305. This expected normalization of earnings is the core bull case for valuation compression.
- Trading Near 52-Week Low, Limited Downside: At $16.52, the stock is just 5.2% above its 52-week low of $15.71, suggesting most negative sentiment is priced in. The Price/Book ratio of 1.49 indicates the market is valuing the company close to its net asset value, providing a valuation floor.
Bearish
- Extremely Elevated Valuation Multiples: The stock trades at a trailing P/E of 156.9x and a forward P/E of 82.6x, which are extreme outliers even for a REIT. These multiples imply an unsustainable expectation for flawless earnings recovery and leave the stock vulnerable to severe multiple compression if estimates are missed.
- Severe Technical Downtrend & Underperformance: The stock is down 17.65% over the past year and 14.71% over six months, significantly underperforming the SPY (+22.2%). It remains in a clear downtrend, trading near 52-week lows, indicating persistent selling pressure and a lack of positive momentum.
- Volatile and Weak Profitability: Net income swung from a $117.1 million loss in Q3 2025 to a $114.0 million profit in Q4, highlighting extreme earnings volatility. The net margin of 2.53% (TTM) is thin, and ROE is a meager 0.95%, indicating poor returns on shareholder equity.
- Interest Rate Sensitivity & Analyst Uncertainty: As a REIT, DOC is highly sensitive to interest rates, which pressure valuations and increase financing costs. Analyst uncertainty is high, with a recent downgrade (Argus to Hold) and a wide EPS estimate range ($0.2802 to $0.32045), reflecting a lack of conviction in the near-term path.
DOC Technical Analysis
The stock is in a sustained downtrend, evidenced by a 1-year price change of -17.65% and a 6-month decline of -14.71%. With a current price of $16.52, it is trading near the lower end of its 52-week range, positioned at approximately 84% of the distance from its 52-week high of $19.68 to its low of $15.71, indicating the stock is in a value zone but remains under significant selling pressure and has not established a definitive bottom. Recent momentum shows a modest divergence, with the stock up 1.98% over the past 3 months but down -5.55% over the past month, suggesting the short-term recovery attempt from the December lows is faltering, potentially signaling a resumption of the primary downtrend or a period of volatile consolidation. Key technical support is clearly defined at the 52-week low of $15.71, while resistance sits at the 52-week high of $19.68; a decisive break below $15.71 would signal a new leg down, whereas a sustained move above the recent recovery highs near $18.50 is needed to suggest a more meaningful reversal. The stock's beta of 1.08 indicates volatility roughly in line with the broader market, though its severe underperformance relative to the SPY, which is up 22.2% over the past year, highlights significant company-specific or sector-specific headwinds.
Beta
1.08
1.08x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$16-$20
Price range past year
Annual Return
-7.9%
Cumulative gain past year
| Period | DOC Return | S&P 500 |
|---|---|---|
| 1m | -1.9% | +0.5% |
| 3m | +0.2% | -2.1% |
| 6m | -7.3% | +4.0% |
| 1y | -7.9% | +29.5% |
| ytd | +3.3% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOC Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $719.4 million representing a 3.07% year-over-year increase; however, the quarterly trend is inconsistent, with revenue dipping in Q3 2025 to $705.9 million before the Q4 rebound, indicating stable but not accelerating top-line expansion primarily driven by its core outpatient medical buildings segment, which generated $626.5 million in the latest period. Profitability is volatile and currently weak, with Q4 2025 net income of $114.0 million and a net margin of 15.84%, a sharp recovery from the Q3 2025 net loss of -$117.1 million; the gross margin for Q4 was an anomalous -87.2%, but this is a GAAP reporting quirk for REITs (high depreciation), with the operating margin of 19.28% and EBITDA margin of 58.7% being more relevant indicators of stable underlying property performance. The balance sheet carries moderate leverage with a debt-to-equity ratio of 1.39, and the company generates substantial cash flow, with TTM free cash flow of $1.17 billion and an operating cash flow of $299.8 million in Q4 2025, providing ample coverage for its dividend (payout ratio of 11.9 based on earnings, but well-covered by cash flow) and capacity to fund its portfolio internally.
Quarterly Revenue
$719402000.0B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
-0.87%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOC Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is extremely elevated at 156.9x, while the forward P/E based on analyst estimates is 82.6x; this wide gap indicates the market is pricing in a significant recovery in earnings, with analysts expecting EPS to rise from $0.16 in Q4 to an estimated $0.305 for the forward period. Compared to sector averages, the stock's valuation presents a mixed picture: its Price/Sales ratio of 3.97 and Price/Book ratio of 1.49 are likely reasonable for a healthcare REIT, but the extreme P/E multiples are outliers driven by depressed near-term earnings rather than sales or asset value. Historically, the stock's current trailing P/E of 156.9x is near the top of its own range over the past several years, which has seen wide swings; for instance, the P/E ratio was 24.6x at the end of Q4 2025 and -28.5x in Q3 2025, indicating the current multiple reflects a period of abnormally low earnings, and a reversion to more normalized profitability would bring the P/E down significantly.
PE
156.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~780x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Healthpeak's primary financial risk is earnings volatility, as evidenced by the swing from a $117.1M loss in Q3 to a $114.0M profit in Q4. While cash flow is strong, the elevated debt-to-equity ratio of 1.39 introduces leverage risk in a rising rate environment, increasing interest expense. Furthermore, the company's valuation is entirely dependent on a swift earnings recovery; the forward P/E of 82.6x leaves no margin for error, creating significant downside if EPS growth stalls below analyst estimates of $0.305.
Market & Competitive Risks: The stock faces acute valuation compression risk, trading at a trailing P/E of 156.9x, a massive premium to historical norms and likely to the sector. As a REIT with a beta of 1.08, it is highly correlated to broader market moves and acutely sensitive to interest rate policy. Sector rotation away from rate-sensitive assets and potential cap rate expansion for healthcare real estate pose persistent headwinds. The stock's 39.8% underperformance versus the SPY over the past year underscores these severe market risks.
Worst-Case Scenario: The worst-case scenario involves a 'stagflation' environment where persistently high interest rates coincide with an economic slowdown that pressures healthcare property occupancy and rental rates. This would cause analyst EPS estimates to be cut, collapsing the forward earnings multiple and triggering a re-rating towards net asset value. A realistic downside could see the stock break its 52-week low of $15.71 and test levels implied by a more normalized, but distressed, P/E. From the current $16.52, this scenario could result in a loss of 15-25%, pushing the stock towards the $12-$14 range.
FAQ
The key risks, in order of severity, are: 1) Valuation & Multiple Compression Risk: The extreme P/E multiples (156.9x trailing) leave the stock vulnerable to a sharp decline if growth stalls. 2) Interest Rate Risk: As a REIT, its cost of capital and asset values are inversely related to interest rates (beta 1.08). 3) Execution/Earnings Risk: Volatile quarterly profits (Q3 loss of -$117.1M to Q4 profit of $114.0M) and a wide analyst EPS range ($0.2802-$0.32045) show high uncertainty in hitting targets. 4) Sector & Macro Risk: The stock has underperformed the SPY by 39.8% over the past year, showing it is out of favor and susceptible to broader real estate sector outflows.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (55% probability) sees the stock trading between $16.50 and $18.00, as it meets analyst EPS estimates of ~$0.305 but struggles with rate headwinds. The Bull Case (25% probability) targets $19.00-$20.50 if earnings beat and rates fall. The Bear Case (20% probability) warns of a drop to $13.00-$15.71 if earnings disappoint and rates remain high. The most likely outcome is the Base Case of range-bound trading, with the key assumption being that DOC achieves the consensus EPS recovery to $0.305.
DOC is overvalued on an earnings basis but fairly valued on an asset and cash flow basis, creating a paradox. The trailing P/E of 156.9x and forward P/E of 82.6x are extremely high, indicating the market is pricing in a near-perfect earnings recovery. However, the Price/Book ratio of 1.49 and Price/Cash Flow ratio of 8.74 are more reasonable, suggesting the underlying property assets and cash generation are not overpriced. The valuation implies the market expects EPS to nearly double from recent levels; if this occurs, the stock could be fairly valued or even cheap. If not, it is significantly overvalued.
DOC is a speculative buy only for specific investor profiles. For income-seeking investors with a long-term horizon (3-5 years), the 7.6% yield supported by strong cash flow is attractive, and buying near 52-week lows offers a margin of safety. However, for most investors, it is not a good buy due to its extreme forward P/E of 82.6x, severe technical downtrend, and sensitivity to interest rates. The stock could be a good buy if an investor believes the earnings recovery will beat expectations and is willing to accept high volatility and potential further downside first.
DOC is suitable only for long-term investment, with a suggested minimum holding period of 3-5 years. The stock's high beta (1.08), sensitivity to interest rate cycles, and need for a multi-quarter earnings recovery narrative make it a poor candidate for short-term trading. Long-term investors can collect the high dividend yield while waiting for macro conditions to improve and for the company's earnings to normalize. The volatile quarterly results and technical downtrend create too much noise for short-term success. This is a stock to buy for yield and potential capital appreciation over a full economic cycle, not for a quick trade.